|
Daniel D. Von Hoff M.D. is Professor of Medicine Molecular and Cellular Biology and Pathology and Director of the Arizona Health Sciences Center’s Cancer Therapeutics Program at The University of Arizona and Director of Translational Research at the Translational Research Institute (Tgen). He is also Chief Scientific Officer for US Oncology Research. Dr. Von Hoff is developing molecularly targeted anticancer therapies with particular concentration in the area of pancreatic cancer. He and his colleagues were involved in the development of mitoxantrone fludarabine paclitaxel docetaxel gemcitabine and CPT-11 and multiple other agents. His laboratory specializes in in-vitro drug sensitivity testing to individualize patient treatment gene amplification and targeting telomere maintenance mechanisms. He is the author of over 503 papers 126 book chapters and 843 abstracts. Dr. Von Hoff is past president of the American Association for Cancer Research a fellow of the American College of Physicians and a member and past board member of the American Society of Clinical Oncology. He is associated in various capacities with many prominent publications as founder editor or co-editor including Investigational New Drugs- The Journal of New Anti-Cancer Agents Clinical Cancer Research and Molecular Cancer Therapeutics. | 